{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018125","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.528541+00:00","generated_at":"2026-06-08T10:12:01.005230+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Harmony Biosciences appoints Peter Anastasiou to Board of Directors","bullets":["Appointed as Class III director effective November 5, 2023; term expires at 2026 annual meeting.","Board expanded from nine to ten members; Anastasiou deemed independent.","Anastasiou is CEO of Capsida Biotherapeutics and former President of North America at Lundbeck.","Will serve on Compensation Committee; brings CNS and business development expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018125","json":"https://secwatch.observer/filing/0001558370-23-018125.json","markdown":"https://secwatch.observer/filing/0001558370-23-018125.md","text":"https://secwatch.observer/filing/0001558370-23-018125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023018125/0001558370-23-018125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023018125/hrmy-20231105x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:12:01.005230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3fa212640","claim":"Peter Anastasiou was appointed as Class III director at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"appointed Peter Anastasiou as a Class III director of the Company with an initial term expiring at the Company’s 2026 annual meeting of stockholders, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023018125/0001558370-23-018125-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}